In 22 treatment-naive adults with HIV-1, oral VH-184 monotherapy (10, 50 or 300 mg on days 1, 4 and 7) gave mean maximum viral load falls of 1.17, 2.15 and 2.31 log10 copies/mL by day 10 versus placebo; no serious AEs or resistance seen.
RCTn = 22
Rogg et al. Proof-of-Concept Phase 2a Trial of VH4524184: An Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile